Literature DB >> 8647946

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.

E Slatopolsky1, J Finch, M Denda, C Ritter, M Zhong, A Dusso, P N MacDonald, A J Brown.   

Abstract

Dietary phosphorus (P) restriction is known to ameliorate secondary hyperparathyroidism in renal failure patients. In early renal failure, this effect may be mediated by an increase in 1,25-(OH)2D3, whereas in advanced renal failure, P restriction can act independent of changes in 1,25-(OH)2D3 and serum ionized calcium (ICa). In this study, we examined the effects of dietary P on serum PTH, PTH mRNA, and parathyroid gland (PTG) hyperplasia in uremic rats. Normal and uremic rats were maintained on a low (0.2%) or high (0.8%) P diet for 2 mo. PTG weight and serum PTH were similar in both groups of normal rats and in uremic rats fed the 0.2% P diet. In contrast, there were significant increases in serum PTH (130 +/- 25 vs. 35 +/- 3.5 pg/ml, P < 0.01), PTG weight (1.80 +/- 0.13 vs. 0.88 +/- 0.06 microg/gram of body weight, P < 0.01), and PTG DNA (1.63 +/- 0.24 vs. 0.94 +/- 0.07 microg DNA/gland, P < 0.01) in the uremic rats fed the 0.8% P diet as compared with uremic rats fed the 0.2% P diet. Serum ICa and 1,25-(OH)2D3 were not altered over this range of dietary P, suggesting a direct effect of P on PTG function. We tested this possibility in organ cultures of rat PTGs. While PTH secretion was acutely (30 min) regulated by medium calcium, the effects of medium P were not evident until 3 h. During a 6-h incubation, PTH accumulation was significantly greater in the 2.8 mM P medium than in the 0.2 mM P medium (1,706 +/- 215 vs. 1,033 +/- 209 pg/microg DNA, P < 0.02); the medium ICa was 1.25 mM in both conditions. Medium P did not alter PTH mRNA in this system, but cycloheximide (10 microg/ml) abolished the effect of P on PTH secretion. Thus, the effect of P is posttranscriptional, affecting PTH at a translational or posttranslational step. Collectively, these in vivo and in vitro results demonstrate a direct action of P on PTG function that is independent of ICa and 1,25-(OH)2D3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647946      PMCID: PMC507339          DOI: 10.1172/JCI118701

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus.

Authors:  H Yi; M Fukagawa; H Yamato; M Kumagai; T Watanabe; K Kurokawa
Journal:  Nephron       Date:  1995       Impact factor: 2.847

2.  In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol.

Authors:  M Aparicio; C Combe; M H Lafage; V de Precigout; L Potaux; J L Bouchet
Journal:  Nephron       Date:  1993       Impact factor: 2.847

3.  Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors.

Authors:  C L Rosenberg; H G Kim; T B Shows; H M Kronenberg; A Arnold
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

4.  Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men.

Authors:  A A Portale; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

Authors:  N Fukuda; H Tanaka; Y Tominaga; M Fukagawa; K Kurokawa; Y Seino
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

6.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.

Authors:  L D Quarles; D A Yohay; B A Carroll; C E Spritzer; S A Minda; D Bartholomay; B A Lobaugh
Journal:  Kidney Int       Date:  1994-06       Impact factor: 10.612

8.  Primary monolayer cell culture of bovine parathyroids: effects of calcium, isoproterenol and growth factors.

Authors:  R R MacGregor; M P Sarras; A Houle; D V Cohn
Journal:  Mol Cell Endocrinol       Date:  1983-06       Impact factor: 4.102

9.  1,25-dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorus restriction.

Authors:  P A Lucas; R C Brown; J S Woodhead; G A Coles
Journal:  Clin Nephrol       Date:  1986-01       Impact factor: 0.975

10.  On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.

Authors:  E Slatopolsky; S Caglar; J P Pennell; D D Taggart; J M Canterbury; E Reiss; N S Bricker
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

View more
  67 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Cycling with the parathyroid.

Authors:  J Silver
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals.

Authors:  Solmaz Khoshniat; Annabelle Bourgine; Marion Julien; Pierre Weiss; Jérôme Guicheux; Laurent Beck
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

5.  Sustained activation of renal N-methyl-D-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT.

Authors:  Eva Parisi; Milica Bozic; Mercé Ibarz; Sara Panizo; Petya Valcheva; Blai Coll; Elvira Fernández; José M Valdivielso
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-09-07       Impact factor: 4.310

6.  Stimulating parathyroid cell proliferation and PTH release with phosphate in organ cultures obtained from patients with primary and secondary hyperparathyroidism for a prolonged period.

Authors:  Kishiko Nakajima; Ken-Ichi Umino; Yoshiaki Azuma; Seiichi Kosaka; Kazue Takano; Takao Obara; Kanji Sato
Journal:  J Bone Miner Metab       Date:  2009-02-06       Impact factor: 2.626

Review 7.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 8.  Management of secondary hyperparathyroidism: how and why?

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2017-01-02       Impact factor: 2.801

9.  Association of serum phosphate with vascular and valvular calcification in moderate CKD.

Authors:  Kathryn L Adeney; David S Siscovick; Joachim H Ix; Stephen L Seliger; Michael G Shlipak; Nancy S Jenny; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 10.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.